1. Perrigo's CEO and CFO will present at a major conference. 2. Company focuses on self-care products with a strong OTC market position. 3. Perrigo's business model combines store brand and leading branded products. 4. Forward-looking statements may impact investor expectations and stock performance. 5. Public can access webcast for further insights into company developments.
Perrigo's participation in a high profile conference indicates positive shareholder engagement and potential strategic growth insights, which could boost investor confidence and stock price. Historical examples show that presentations at significant financial events often lead to positive stock movements for companies that clarify their strategies or provide optimistic forecasts.
This article's content is crucial as it relates to upcoming events affecting PRGO's stock performance and market perception. The positive openness about self-care innovations aligns with market trends emphasizing health and wellness, making it relevant for investors.
The impact from the conference is likely to be immediate, as investor sentiment and stock reactions may occur based on announcements or insights shared. Previous presentations often lead to short-term stock price adjustments reflecting market reactions.
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference, being conducted virtually on Tuesday, June 10 at 9 AM ET.
Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.
Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.
Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Solpadeine®.
For more information, visit www.perrigo.com.
This press release includes, and the matters discussed in Perrigo's presentation at the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference will include certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995', as amended. Forward-looking statements relate to future events and involve known and unknown risks, uncertainties and other factors—many of which beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2024.
Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications; (269) 686-3373; e-mail: bradley.joseph@perrigo.com
Nicholas Gallagher, Senior Manager, Global Investor Relations & Corporate Communications; (269) 686-3238, e-mail: nicholas.gallagher@perrigo.com
SOURCE Perrigo Company plc